AKRON, Ohio, Nov. 11, 2026 /PRNewswire/ — Resivant Medical today announced broadening use of its Cutiva® PLUS Skin Closure System across orthopedic, sports medicine, spine, plastic and pediatric surgery. Now used at multiple healthcare facilities following its first clinical cases in June, Cutiva® PLUS is bringing the company’s next-generation adhesive technology into diverse surgical settings.
Surgeons and physicians’ assistants report positive experiences with ease of application, wound closure strength, and flexibility. Cutiva® PLUS has now been used to close incisions for orthopedic specialties including hip and knee replacement, shoulder arthroplasty, and spine surgery, sports medicine including Achilles tendon and ACL repair, and has also been successfully used in plastic surgery and pediatric procedures. “Our mission is to establish a new standard of care in skin closure,” said Darren Obrigkeit, CEO of Resivant Medical. “We designed Cutiva® PLUS around a clear purpose: to bring easy application, strong incision closure, microbial barrier seal, and peel-off removal convenience together in one system that also provides unsurpassed patient safety. “Seeing surgical teams put that design to work across multiple surgical specialties verifies the performance of Cutiva® PLUS in everyday clinical practice.”
Built on Resivant’s proprietary crosslinked silicone cyanoacrylate adhesive technology, Cutiva® PLUS brings easy, single-handed application, strong and flexible incision closure, and peel-off removal together in one adhesive-and-mesh system. The adhesive forms a seal over the incision and provides a microbial barrier.
Resivant continues to onboard clinical sites as it expands the commercial reach of the Cutiva® PLUS product family.
About Resivant Medical:
Resivant Medical is developing next-generation medical adhesive technologies designed to enhance wound closure for patients and healthcare professionals. Its portfolio of skin closure adhesive products is designed for topical application on wounds and surgical incisions.
For more information, visit www.resivant.com. Email: investors@resivant.com
Media Contact
Lindsey Dinneen
Director of Marketing & Engagement
Project Medtech
lindsey.dinneen@projectmedtech.com
SOURCE Resivant Medical
